Patient characteristics at presentation
| Baseline characteristics . | Caplacizumab cohort . |
|---|---|
| N = 16, 100% | |
| Age, median (range), mo | 14 y and 9 mo (2 y 9 mo to 17 y 17 mo) |
| Body weight, kg, median (range) | 63.2 (15.3-101) |
| Sex | |
| Male | 6 |
| Female | 10 |
| Ethnicity | |
| Black | 6 |
| White | 5 |
| Asian | 2 |
| Mixed race | 3 |
| Clinical features | |
| Neurological symptoms at presentation | 10 |
| Confusion | |
| Headache | 5 (including agitation in 1) 5 (including memory loss in 1) |
| Intensive care | 3 |
| Patients requiring intubation | 1 |
| Baseline characteristics . | Caplacizumab cohort . |
|---|---|
| N = 16, 100% | |
| Age, median (range), mo | 14 y and 9 mo (2 y 9 mo to 17 y 17 mo) |
| Body weight, kg, median (range) | 63.2 (15.3-101) |
| Sex | |
| Male | 6 |
| Female | 10 |
| Ethnicity | |
| Black | 6 |
| White | 5 |
| Asian | 2 |
| Mixed race | 3 |
| Clinical features | |
| Neurological symptoms at presentation | 10 |
| Confusion | |
| Headache | 5 (including agitation in 1) 5 (including memory loss in 1) |
| Intensive care | 3 |
| Patients requiring intubation | 1 |